Trial Profile

A Phase 1 Clinical Study of Autologous HBV-specific TCR-T Cell Therapy (SCG101) in Patients With HBV-related HCC

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SCG 101 (Primary) ; Checkpoint kinase inhibitors; Cyclophosphamide; Fludarabine
Indications Liver cancer
Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

08 May 2025 According to a SCG Cell Therapy media release, data from this study were presented at the European Association for the Study of the Liver (EASL) Congress 2025.
08 May 2025 Results presented in a SCG Cell Therapy media release.
25 Nov 2024 According to a SCG Cell Therapy media release, late-breaking data from its Phase 1 trial of SCG101 was presented at the 2024 AASLD Liver Meeting in San Diego, United States.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com